Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical Developments International has launched its analgesic pain relief drug, in Italy.
  • Penthrox is a fast-acting pain relief drug which has had highly positive test results during various studies
  • The company is pleased to have entered the Italian market and is expected a $2 million payment from its long-time partner, Mundipharma in 2020
  • Medical Developments International’s shares are slightly down 2.25 per cent, with shares trading at $5.66 apiece

Medical Developments International has launched its analgesic pain relief drug, in Italy.

There have been a significant number of clinical studies conducted in preparation for this launch.

In particular, a study of 272 trauma patients in 15 Italian emergency units showed that Penthrox was superior to Standard of Care, including Opioids, for adult trauma patients.

Penthrox is a fast-acting trauma and emergency pain relief product. It is currently a widely-used treatment in Australian Hospitals.

Yesterday on the Australian Securities Exchange, the company announced positive results during a recent European study.

The study showed Penthrox was dominant over placebo cases and effective in relieving pain in patients who have undergone surgery.

“We are delighted to finally launch Penthrox in the important European market of Italy,” MDI CEO John Sharman said.

“The launch of Penthrox in Italy will trigger another milestone payment from our partner Mundipharma of US$2million which is expected during 2020,” he continued.

Mundipharma is a global network of privately-owned independent companies who aims to move medicine forward. Through partnerships, it has diversified its European portfolio to create value for patients and wider healthcare systems.

“We see this inhaled analgesic as an important medication for trauma patients here and throughout Europe and we look forward to our continued collaboration with MDI,” Mundipharma’s European Launch and Asset Lead Maya Marescotti said.

Medical Developments International’s shares are slightly down 2.25 per cent, with shares trading at $5.66 apiece as at 3:59 pm AEDT.

MVP by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.